K.S. Lee co-founded Silicon Image, Inc. in Silicon Valley, U.S. a developer of semiconductors for communications applications in 1994, and served as the Vice President of Strategic Alliance. He had an experience for successful IPO of Silicon Image in 1999. After that, he was the founding CEO of GCT Semiconductor, a fabless semiconductor company in the United States that designs, develops, and markets innovative integrated circuit solutions for the wireless communications industry. He graduated from electrical engineering department in Hanyang University.

Presently In Chull Kim is President of Corporate Strategy, Kainos Medicine. From 2011 up to 2017 he had been the CEO & President, National OncoVenture that was anti-cancer new drug development program sponsored by Korean government. From 1993 to 2011 he had been at various director’s positions and also served as the CEO & President of LG Life Sciences. In 1985 he had received his Ph.D. degree from University of Illinois, since then he worked as the research fellow at the Rockefeller University and Duke Medical Center. Prior to coming back to Korea in 1993 he worked as the Research Investigator at the Glaxo, Inc., USA.

Dr. Lee earned his Ph.D. in Biochemistry/Genetics at Duke University in 1989 after receiving MS at KAIST and B.S. in Biology at Sogang University in Seoul. After postdoctoral training under Dr. Arno Greenleaf in Biochemistry at Duke University, he was a research assistant professor jointly under Dr. Robert Lefkowitz (2012 Nobel Prize Laureate) and Dr. Marc Caron in Cell Biology at Duke University. Then, he moved to pharmaceutical industry and worked for ACLARA Biosciences, EXELIXIS Pharmaceuticals, and ARAGEN Bioscience in US for 14 years. While in EXELIXIS for 10 years, he was a key contributor and project leader that implemented 8 pipelines of cancer drugs, including drugs targeting protein kinases, and anti-metabolic drugs. Also, he has experienced in ARAGEN with developing anti-cancer biotherapeutic drugs such as cancer vaccines, monoclonal antibodies and complex immunotoxin therapeutics. As the VP of Biology, he is currently focusing on the clinical development of KM-819 for Parkinson’s disease. Also, as a Chief Business Officer, he has been working on licensing and other company business.